Vimarsana
Biggest News Aggregation in the World

Genome Stability News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genome Stability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genome Stability Today - Breaking & Trending Today

UCD professor wins ERC Synergy grant to unlock the secrets to healthy aging - Vimarsana News

UCD professor wins ERC Synergy grant to unlock the secrets to healthy aging

Do bats hold the secret to health and longevity? A team led by Professor Emma Teeling, Full Professor of Zoology at University College Dublin (UCD), has won a prestigious European Research Council (ERC) Synergy grant of almost €12 million, to explore this fascinating question.

Vendor notebook: New AI tools to cut billing burdens, improve testing and more - Vimarsana News

Vendor notebook: New AI tools to cut billing burdens, improve testing and more

Femtech developer Aspira Women's Health signs with Dana Farber to license a biomarker-based ovarian cancer diagnostic, a Madrona Venture Labs spin-out adds GPT-enabled virtual agents to billing automation and Dave, an LLM oncology tool, is born.

Radiation damage to paternal DNA is passed on to offspring - Vimarsana News

Radiation damage to paternal DNA is passed on to offspring

Whether radiation exposure of fathers can have consequences on their children is one of the most long-standing questions in radiation biology.

Radiation damage to mature sperm cannot be repaired and is instead passed on to the offspring - Vimarsana News

Radiation damage to mature sperm cannot be repaired and is instead passed on to the offspring

Whether radiation exposure of fathers can have consequences on their children is one of the most long-standing questions in radiation biology.

AstraZeneca: LYNPARZA (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials - Vimarsana News

AstraZeneca: LYNPARZA (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials

Landmark 5-year follow-up of PAOLA-1 Phase III trial demonstrated LYNPARZA plus bevacizumab meaningfully extended survival with 65.5% of HRD-positive patients surviving 5 years vs. 48.4% treated with